FDA Drug Abuse Advisory Committee
Executive Summary
Status of Astra's Dalgan Injection (dezocine) postmarketing surveillance of abuse and diversion will be addressed at the Feb. 4 meeting. Panel also will discuss the abuse liability of Bristol- Myers Squibb's Stadol Nasal Spray (butorphanol tartrate). On Feb. 5, the committee will address guideline development for assessing abuse liability of drugs and the status of guideline development for medications to treat drug dependence and abuse. Committee will meet at 9 a.m. both days at FDA's Parklawn building in conference rooms D & E.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth